Search hospitals > Wisconsin > Burlington
Aurora Cancer Care-Southern Lakes VLCC
Claim this profileBurlington, Wisconsin 53105
Global Leader in Cancer
Global Leader in Breast Cancer
Conducts research for Lung Cancer
Conducts research for Non-Small Cell Lung Cancer
Conducts research for Recurrence
184 reported clinical trials
21 medical researchers
Summary
Aurora Cancer Care-Southern Lakes VLCC is a medical facility located in Burlington, Wisconsin. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Non-Small Cell Lung Cancer, Recurrence and other specialties. Aurora Cancer Care-Southern Lakes VLCC is involved with conducting 184 clinical trials across 303 conditions. There are 21 research doctors associated with this hospital, such as Rubina Qamar, Thomas J. Saphner, Antony Ruggeri, and Michael A Thompson.Area of expertise
1Cancer
Global LeaderStage IV
Stage III
Stage II
2Breast Cancer
Global LeaderER positive
HER2 negative
HER2 positive
Top PIs
Rubina QamarAurora Saint Luke's Medical Center1 year of reported clinical research
Expert in Breast Cancer
Expert in Cancer
26 reported clinical trials
72 drugs studied
Thomas J. SaphnerAurora Saint Luke's Medical Center4 years of reported clinical research
Expert in Cancer
Studies Breast Cancer
27 reported clinical trials
57 drugs studied
Antony RuggeriAurora Cancer Care-Milwaukee West4 years of reported clinical research
Studies Cancer
Studies Colorectal Cancer
14 reported clinical trials
57 drugs studied
Michael A ThompsonAurora Cancer Care-Milwaukee West3 years of reported clinical research
Studies Multiple Myeloma
Studies Plasma Cell Neoplasms
12 reported clinical trials
29 drugs studied
Clinical Trials running at Aurora Cancer Care-Southern Lakes VLCC
Breast Cancer
Non-Small Cell Lung Cancer
Cancer
Lung Cancer
Prostate Cancer
Bladder Carcinoma
Renal Cell Carcinoma
Ovarian Cancer
Rectal Cancer
Bladder Cancer
Durvalumab + Chemotherapy
for Breast Cancer
This phase III trial compares the addition of an immunotherapy drug (durvalumab) to usual chemotherapy versus usual chemotherapy alone in treating patients with MammaPrint Ultrahigh (MP2) stage II-III hormone receptor positive, HER2 negative breast cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as paclitaxel, doxorubicin, and cyclophosphamide work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. There is some evidence from previous clinical trials that people who have a MammaPrint Ultrahigh Risk result may be more likely to respond to chemotherapy and immunotherapy. Adding durvalumab to usual chemotherapy may be able to prevent the cancer from returning for patients with MP2 stage II-III hormone receptor positive, HER2 negative breast cancer.
Recruiting2 awards Phase 340 criteria
Hormone Therapy with or without Radiation
for Breast Cancer
This Phase III Trial evaluates whether breast conservation surgery and endocrine therapy results in a non-inferior rate of invasive or non-invasive ipsilateral breast tumor recurrence (IBTR) compared to breast conservation with breast radiation and endocrine therapy.
Recruiting2 awards Phase 313 criteria
Support Program
for Breast Cancer
This phase III trial compares an additional support program (text message reminders and/or telephone-based counseling) with usual care in making sure breast cancer patients take their endocrine therapy medication as prescribed (medication adherence). Medication adherence is how well patients take the medication as prescribed by their doctors, and good medical adherence is when patients take medications correctly. Poor medication adherence has been shown to be a serious barrier to effective treatment for hormone receptor positive breast cancer patients. Adding text message reminders and/or telephone-based counseling to usual care may increase the number of days that patients take their endocrine therapy medication as prescribed.
Recruiting2 awards Phase 34 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Aurora Cancer Care-Southern Lakes VLCC?
Aurora Cancer Care-Southern Lakes VLCC is a medical facility located in Burlington, Wisconsin. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Non-Small Cell Lung Cancer, Recurrence and other specialties. Aurora Cancer Care-Southern Lakes VLCC is involved with conducting 184 clinical trials across 303 conditions. There are 21 research doctors associated with this hospital, such as Rubina Qamar, Thomas J. Saphner, Antony Ruggeri, and Michael A Thompson.